Q3 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Appendix
Innovation: Clinical trials
Innovation: Pipeline overview
References
Broad pipeline of novel medicines continued to evolve in Q3
Core therapeutic areas
Cardiovascular
Approvals
Immunology
Neuroscience
503 Solid tumors
Hematology
Scemblix®
EU: CML 3L
KymriahⓇ
JP: r/r follicular lymphoma
CosentyxⓇ
JP: 300mg auto-injector
Readouts and publications
Abbreviations
Iptacopan
Canakinumab
Tislelizumab
Ph3 - PNH
UNR844
Ph3 Adjuvant NSCLC (PE not met)
Ph3 1L HCC (BeiGene study)
Ph2 - Presbyopia (PE not met)
Designations and milestones
M
PluvictoⓇ
mCRPC CHMP positive opinion (post Q3)
Incl. for Locametz (imaging agent)
lanalumab
Ph3 Lupus Nephritis SIRIUS-LN initiated
lanalumab
-
Ph3 Sjögren's NEPTUNUS-1 and -2 initiated
Submissions
CosentyxⓇ
Tafinlar® +
MekinistⓇ
XolairⓇ
US: Hidradenitis suppurativa
US: Pediatric Low-Grade Glioma
(granted FDA priority review)
US and EU: Auto-injector
Selected milestones PE: Primary Endpoint
32 Investor Relations | Q3 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation